Inclusion-body myositis in the elderly: An update

Aging Health

Volumn 6, Issue 6, 2010, Pages 687-694

  Schmidt, Jens ^a,b   Dalakas, Marinos C ^c,d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Gemeinnutzige Hertie Stiftung   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

B crystallin; amyloid; aging; autoimmunity; cell stress; cytotoxic T cell; IL 1; muscle inflammation; myopathy; myositis; neuromuscular disease; protein aggregation

Indexed keywords

ALEMTUZUMAB; ALPHA CRYSTALLIN; AMYLOID BETA PROTEIN; BETA CRYSTALLIN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AUTOPHAGY; CELLULAR STRESS RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELDERLY CARE; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; HAPLOTYPE; HUMAN; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; MUSCLE BIOPSY; NONHUMAN; ONSET AGE; REVIEW; T CELL DEPLETION;

EID: 78650293115     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.10.64     Document Type: Review

References (72)

1. Dalakas MC: Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Pract. Neurol. 2(8), 437-447 (2006).
2. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21(1), 115-117 (1998).
3. Badrising UA, Schreuder GMT, Giphart MJ, et al.: Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63(12), 2396-2398 (2004).
4. Needham M, James I, Corbett A, et al.: Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J. Neurol. Neurosurg. Psychiatry 79(9), 1056-1060 (2008).
5. Mastaglia FL, Needham M, Scott A, et al.: Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul. Disord. 19(11), 763-765 (2009).
6. Needham M, Corbett A, Day T, et al.: Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J. Clin. Neurosci. 15(12), 1350-1353 (2008).
7. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J. Neuropathol. Exp. Neurol. 55(3), 342-347 (1996).
8. De Bleecker JL, Meire VI, Declercq W, Van Aken EH: Immunolocalization of tumor necrosis factor-a and its receptors in inflammatory myopathies. Neuromuscul. Disord. 9(4), 239-246 (1999).
9. Dalakas MC: Molecular immunology and genetics of inflammatory muscle diseases. Arch. Neurol. 55(12), 1509-1512 (1998).
10. De Paepe B, Creus KK, De Bleecker JL: Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 21(6), 610-616 (2009).
11. De Paepe B, Creus KK, De Bleecker JL: Chemokines in idiopathic inflammatory myopathies. Front Biosci. 13 2548-2577 (2008).
12. Confalonieri P, Bernasconi P, Megna P, et al.: Increased expression of β-chemokines in muscle of patients with inflammatory myopathies. J. Neuropathol. Exp. Neurol. 59(2), 164-169 (2000).
13. De Rossi M, Bernasconi P, Baggi F, de Waal MR, Mantegazza R: Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int. Immunol. 12(9), 1329-1335 (2000).
14. De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM: Differential expression of chemokines in inflammatory myopathies. Neurology 58(12), 1779-1785 (2002).
15. Raju R, Vasconcelos O, Granger R, Dalakas MC: Expression of IFN-g-inducible chemokines in inclusion body myositis. J. Neuroimmunol. 141(1-2), 125-131 (2003).
16. De Bleecker JL, Engel AG: Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J. Neuropathol. Exp. Neurol. 53(4), 369-376 (1994).
17. Choi YC, Dalakas MC: Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54(1), 65-71 (2000).
18. Kieseier BC, Schneider C, Clements JM, et al.: Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 124(Pt 2), 341-351 (2001).
19. Goebels N, Michaelis D, Wekerle H, Hohlfeld R: Human myoblasts as antigen-presenting cells. J. Immunol. 149(2), 661-667 (1992).
20. van der Pas J, Hengstman GJD, ter Laak HJ, Borm GF, van Engelen BGM: Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 75(1), 136-139 (2004).
21. Wiendl H, Mitsdoerffer M, Schneider D, et al.: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126(Pt 5), 1026-1035 (2003).
22. Schmidt J, Rakocevic G, Raju R, Dalakas MC: Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127 1182-1190 (2004).
23. Sugiura T, Kawaguchi Y, Harigai M, et al.: Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J. Immunol. 164(12), 6593-6600 (2000).
24. Salajegheh M, Raju R, Schmidt J, Dalakas MC: Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis. J. Neuroimmunol. 187(1-2), 166-174 (2007).
25. Waschbisch A, Wintterle S, Lochmuller H, et al.: Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum. 58(11), 3600-3608 (2008).
26. Wiendl H, Mitsdoerffer M, Schneider D, et al.: Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 17(13), 1892-1894 (2003).
27. Wiendl H, Behrens L, Maier S, et al.: Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann. Neurol. 48(4), 679-684 (2000).
28. Wiendl H, Hohlfeld R, Kieseier BC: Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26(7), 373-380 (2005).
29. Dimitri D, Benveniste O, Dubourg O, et al.: Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 129(Pt 4), 986-995 (2006).
30. Salajegheh M, Rakocevic G, Raju R, et al.: T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69(17), 1672-1679 (2007).
31. Fyhr IM, Moslemi AR, Mosavi AA, et al.: Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J. Neuroimmunol. 79(2), 185-189 (1997).
32. Lindberg C, Oldfors A, Tarkowski A: Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur. J. Immunol. 24(11), 2659-2663 (1994).
33. OHanlon TP, Dalakas MC, Plotz PH, Miller FW: Predominant TCR-ab variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J. Immunol. 152(5), 2569-2576 (1994).
34. Benveniste O, Herson S, Salomon B, et al.: Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann. Neurol 56(6), 867-872 (2004).
35. Dalakas MC: Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat. Clin. Pract. Rheumatol. 2(4), 219-227 (2006).
36. Amemiya K, Granger RP, Dalakas MC: Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123(Pt 10), 2030-2039 (2000).
37. Hofbauer M, Wiesener S, Babbe H, et al.: Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc. Natl Acad. Sci. USA 100(7), 4090-4095 (2003).
38. Goebels N, Michaelis D, Engelhardt M, et al.: Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97(12), 2905-2910 (1996).
39. Hohlfeld R, Engel AG: Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann. Neurol. 29(5), 498-507 (1991).
40. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL: Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 35(1), 17-23 (2007).
41. Bradshaw EM, Orihuela A, McArdel SL, et al.: A local antigen-driven humoral response is present in the inflammatory myopathies. J. Immunol. 178(1), 547-556 (2007).
42. Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65(11), 1782-1787 (2005).
43. Askanas V, Engel WK: Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr. Opin. Rheumatol. 19(6), 550-559 (2007).
44. Fratta P, Engel WK, McFerrin J, et al.: Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-b precursor protein-overexpressing cultured human muscle fibers. Am. J. Pathol. 167(2), 517-526 (2005).
45. Vattemi G, Engel WK, McFerrin J, et al.: Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 358(9297), 1962-1964 (2001).
46. De Paepe B, Racz GZ, Schroder JM, De Bleecker JL: Expression and distribution of the nitric oxide synthases in idiopathic inflammatory myopathies. Acta Neuropathol. (Berl.) 108(1), 37-42 (2004).
47. Tews DS, Goebel HH: Cell death and oxidative damage in inflammatory myopathies. Clin. Immunol. Immunopathol. 87(3), 240-247 (1998).
48. Wanchu A, Khullar M, Sud A, Bambery P: Nitric oxide production is increased in patients with inflammatory myositis. Nitric Oxide 3(6), 454-458 (1999).
49. Yang CC, Alvarez RB, Engel WK, Heller SL, Askanas V: Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies. Brain 121 1089-1097 (1998).
50. Kumamoto T, Ueyama H, Tsumura H, Toyoshima I, Tsuda T: Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis. Acta Neuropathol. 107(1), 59-65 (2004).
51. Ventruti A, Cuervo AM: Autophagy and neurodegeneration. Curr. Neurol. Neurosci. Rep. 7(5), 443-451 (2007).
52. Lunemann JD, Schmidt J, Schmid D, et al.: β-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann. Neurol. 61(5), 476-483 (2007). (Pubitemid 46878775)
53. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8(9), 741-752 (2007).
54. Schmid D, Munz C: Localization and MHC class II presentation of antigens targeted for macroautophagy. Methods Mol. Biol. 445, 213-225 (2008).
55. Pruitt JN, Showalter CJ, Engel AG: Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39(1), 139-143 (1996).
56. Fukuchi K, Pham D, Hart M, Li L, Lindsey JR: Amyloid-b deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am. J. Pathol. 153(6), 1687-1693 (1998).
57. Jin LW, Hearn MG, Ogburn CE, et al.: Transgenic mice over-expressing the C-99 fragment of bPP with an a-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am. J. Pathol. 153(6), 1679-1686 (1998).
58. Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Ab42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am. J. Pathol. 168(6), 1986-1997 (2006).
59. Sugarman MC, Kitazawa M, Baker M, et al.: Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol. Aging 27(3), 423-432 (2006).
60. Sugarman MC, Yamasaki TR, Oddo S, et al.: Inclusion body myositis-like phenotype induced by transgenic overexpression of b APP in skeletal muscle. Proc. Natl Acad. Sci. USA 99(9), 6334-6339 (2002).
61. Nagaraju K, Raben N, Loeffler L, et al.: Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl Acad. Sci. USA 97(16), 9209-9214 (2000).
62. Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. 185(2), 119-122 (2001).
63. Dalakas MC, Sonies B, Dambrosia J, et al.: Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48(3), 712-716 (1997).
64. Schmidt J, Barthel K, Wrede A, et al.: Interrelation of inflammation and APP in sIBM: IL-1b induces accumulation of β-amyloid in skeletal muscle. Brain 131(Pt 5), 1228-1240 (2008).
65. Kitazawa M, Trinh DN, LaFerla FM: Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3b. Ann. Neurol. 64(1), 15-24 (2008).
66. Goldfarb LG, Vicart P, Goebel HH, Dalakas MC: Desmin myopathy. Brain 127(Pt 4), 723-734 (2004).
67. Banwell BL, Engel AG: α B-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54(5), 1033-1041 (2000).
68. Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J: Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of αB-crystallin is associated with amyloid precursor protein and accumulation of β-amyloid. J. Neurol. Neurosurg. Psychiatry 80(12), 1344-1349 (2009).
69. Rossi P, Marzani B, Giardina S, Negro M, Marzatico F: Human skeletal muscle aging and the oxidative system: cellular events. Curr. Aging Sci. 1(3), 182-191 (2008).
70. Dalakas MC: Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". Ann. Neurol. 64(1), 1-3 (2008).
71. Dalakas MC, Rakocevic G, Schmidt J, et al.: Effect of alemtuzumab (Campath 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6), 1536-1544 (2009).
72. Hughes RA, Dalakas MC, Cornblath DR, et al.: Clinical applications of intravenous immunoglobulins in neurology. Clin. Exp. Immunol. 158(Suppl. 1), 34-42 (2009).